Chinese maker of zirconia and other ceramic dental-restoration materials for CAD/CAM dental labs.
Chinese maker of zirconia and other ceramic dental-restoration materials for CAD/CAM dental labs.
Zirconia blocks are consumables milled into crowns and bridges, so sales recur with the number of restorations. The shift of dental labs from hand-made to digitally milled work expands the market for such blocks.
In one line: A Chinese Ivoclar/3M dental-ceramics supplier.
Moat: narrow (process know-how, brand). Ceramic material formulation know-how differentiates strength/aesthetics for dental labs.
Headquarters: Qinhuangdao, Hebei, China · Employees: 1,303
Size Aidite (Qinhuangdao) Technology (301580.SZ) is a China Health Care company (Medical Specialties) with a market value of $888M, the 2387th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥39.94 on 18 Nov 2026.
Performance Over six months the shares fell 11.7%, against -13.6% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 16.5% over the last twelve months (peer median +6.0%); the operating margin is 17.8% (peer median 9.0%).
Valuation It trades at 26.2× forward earnings against a peer median of 20.9× (7th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 7.9 points above its cost of capital (11.5% WACC).
Next results Next results expected around 5 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.16B | CN¥1.03B | CN¥884M | CN¥774M | CN¥601M |
| Revenue growth | — | +16% | +14% | +29% | — |
| Gross profit | CN¥628M | CN¥503M | CN¥441M | CN¥367M | CN¥265M |
| EBITDA | n/a | CN¥212M | CN¥190M | CN¥157M | CN¥108M |
| Net income | CN¥202M | CN¥196M | CN¥150M | CN¥147M | CN¥116M |
| Free cash flow | CN¥114M | CN¥219M | CN¥68.1M | CN¥118M | CN¥179M |
| Capital expenditure | CN¥123M | CN¥68.8M | CN¥84.4M | CN¥33.2M | CN¥44.5M |
| Total debt | CN¥29.3M | CN¥28.7M | CN¥7.06M | CN¥1.40M | CN¥44.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Aidite (Qinhuangdao) Technology 301580.SZ | $888M | -12% | +17% | 18% | 26.2× | 19.3% |
| 3M MMM | $93.6B | +22% | +2% | 21% | 18.8× | 11.3% |
| DENTSPLY SIRONA XRAY | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301580.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.4% | -5.1% | 9th lowest of 21 |
| 6-month return | -11.7% | -13.6% | 9th highest of 21 |
| Distance from 52-week high | -54.6% | -40.0% | 6th lowest of 21 |
| Revenue growth (TTM) | +16.5% | +6.0% | 5th highest of 21 |
| Operating margin | 17.8% | 9.0% | 5th highest of 21 |
| Forward P/E | 26.2× | 20.9× | 7th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 19.3% | 3.3% | 4th most demanding of 14 |
| Growth delivered (Del g) | +23.3% | +11.7% | highest of 14 |
| Hurdle (Req g minus delivered) | -4.0 pp | -4.6 pp | 7th most demanding of 14 |
| ROIC minus cost of capital | +7.9 pp | +2.0 pp | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $888M | -12% | +17% | 18% | 26.2× | 19.3% | +23.3% |
| Shenzhen YHLO Biotech 688575.SS | China | $882M | -16% | +3% | 12% | 30.7× | 2.0% | +12.7% |
| Bioventus BVS | United States | $895M | -3% | +4% | 10% | 13.0× | 7.5% | +12.1% |
| Hangzhou Biotest Biotech 688767.SS | China | $878M | -12% | -4% | 3% | 37.0× | n/a | n/a |
| Xiangyu Medical 688626.SS | China | $877M | -38% | 0% | 4% | 56.2× | n/a | n/a |
| Artivion AORT | United States | $905M | -18% | +14% | 5% | 383.6× | n/a | n/a |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |
| Kuros Biosciences KURN.SW | Switzerland | $907M | -12% | +41% | 6% | 70.5× | n/a | n/a |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | n/a | 32.6% | +21.0% |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 20.9× | n/a | n/a |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 15.8× | 1.3% | +4.7% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 18.7× | -6.1% | +11.7% |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 19.9× | 3.3% | +13.9% |